NUS Enterprise

Mouse Anti-CD137 Ligand (Clone 1C8E9)

Technology #14175n

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Collections
Categories
Managed By
Dr Esther Lee
Manager (65)65166398
Publications
CD137L dendritic cells induce potent response against cancer-associated viruses and polarize human CD8+ T cells to Tc1 phenotype
Cancer Immunol Immunother , 2018, Mar 5
Files and Attachments
Anti_CD137L_MS_1C8E9.pdf [PDF]

PRODUCT NAME 

Anti – CD137 Ligand 

BACKGROUND INFOMATION 

CD137 and CD137 ligand interaction is important in transplant rejection, pathogen 
clearance and protection against malignant diseases. The study of CD137 ligand may 
be used for evaluating the potential predictive and correlative functions in oncology in 
preclinical and clinical studies and may assist in answering certain crucial questions that 
may be useful for the study of Cancer. 

PRODUCT DESCRIPTION 

This antibody is a monoclonal antibody that recognises the cytoplasmic domain of the 
CD137 ligand. CD137 ligand is expressed in B cell lymphoma and myeloma cell line. 

FORMAT 

100μg of lyophilized, purified antibody. Reconstitute to 100μl of distilled H2O for 1μg/μl. It 
contains no additives. 

HOST 

Mouse 

CLONALITY 

Monoclonal 

ISOTYPE 

Human IgG1 

REACTIVITY/ SPECIFICITY 

This antibody is highly specific for the cytoplasmic domain of the CD137 ligand. 

APPLICATIONS 

Immunoflourescence (IF), Western Blot (WB), Immunoprecipitate (IP) 

RECOMMENDED STARTING DILUTIONS 

IF / IP: 1:1000. WB: 1:500. Optimal dilution has to be determined by the user. 

STORAGE 

Lyophilized antibody can be kept at 4°C for up to 3 months and should be kept at -20°C 
for long-term storage. To avoid freeze-thaw cycles, reconstituted antibody should be 
aliquoted before freezing for short-term storage (-20°C) or for long-term storage (-80°C). 
For maximum recovery of product, centrifuge the original vial prior to removing the cap. 
Further dilutions can be made in assay buffer. 

STABILITY 

Minimum 1 year from reception date. 

REFERENCES 

Dharmadhikari B, Nickles E, Harfuddin Z, Ishak NDB, Zeng Q, Bertoletti A, Schwarz H. 
CD137L dendritic cells induce potent response against cancer-associated viruses and 
polarize human CD8+ T cells to Tc1 phenotype. Cancer Immunol Immunother 2018, Mar 5. 

Rajendran S, Ho WT, Schwarz H. CD137 signaling in Hodgkin and Reed-Sternberg cell 
lines induces IL-13 secretion, immune deviation and enhanced growth. Oncoimmunology 
2016 Apr 29; 5(6). 

Harfuddin Z, Dharmadhikari B, Wong SC, Duan K, Poidinger M, Kwajah S, Schwarz H. 
Transcriptional and functional characterization of CD137L-dendritic cells identifies a 
novel dendritic cell phenotype. Sci Rep 2016 Jul 19;629712 

Dharmadhikari B, Wu M, Abdullah NS, Rajendran S, Ishak ND, Nickles E, Harfuddin Z, 
Schwarz H. CD137 and CD137L signals are man drivers of type 1, cell-mediated 
immune responses. Oncoimmunology 2015 Nov 11; 5(4) 
Shao Z, Harfuddin Z, Pang WL, Nickles E, Koh LK, Schwarz H. 
Trogocytic CD137 transfer causes an internalization of CD137 ligand on murine APCs 
leading to reduced T cell costimulation. J Leukoc. Biol. 2015 May; 97 

LIMITATIONS 

This product has to be used for research purposes only.